ライフサイエンスコーパス: plaque-forming

1 alpha-P and BACE1 are elevated in aggressive plaque-forming 5XFAD transgenic mice, and BACE1, eIF2alp

2 The use of a small plaque-forming A36R gene deletion mutant to select spont

3 ut they were robust in viral replication and plaque forming ability.

4 transdominant or potentiating effect on the plaque-forming ability of infectious DNA from wild-type

5 fold lower titers) in nondividing cells, and plaque-forming ability was severely compromised.

6 ss-links resulted in very severely decreased plaque-forming ability, along with an increased mutageni

7 in hydrolase (gp61) that is essential for N4 plaque-forming ability.

8 showed greatly reduced (around 100,000-fold) plaque-forming ability.

9 ssay of full-length transcripts to determine plaque-forming ability; and (iv) analysis of proteins ex

10 Rs of the APP superfamily, including amyloid plaque-forming and non-amyloid plaque-forming species, a

11 tly increased microglial density and size in plaque-forming areas of hippocampus and frontal, entorhi

12 re evaluated by using real-time PCR, a viral plaque-forming assay, and immunofluorescence staining.

13 V-1 inactivation was measured in a sensitive plaque-forming assay, and the corresponding level of CD4

14 Viral plaque forming assays evaluated G207 replication.

15 Using the iLLO strain in plaque-forming assays, we demonstrated an additional req

16 DDN in inhibiting dengue virus infection via plaque-forming assays.

17 Unlike CJ83193, which exhibits limited plaque-forming capability in Vero cells and expresses li

18 their capacity to mount an in vitro antibody plaque-forming cell (PFC) response to sheep erythrocytes

19 sed in their ability to generate an in vitro plaque-forming cell (PFC) response to sheep erythrocytes

20 acity of splenocytes to generate an in vitro plaque-forming cell (PFC) response to sheep erythrocytes

21 of spleen cells to mount a primary, in vitro plaque-forming-cell (PFC) response to sheep erythrocytes

22 Plaque-forming characteristics and RFLP analyses of phag

23 with UBE2D1 fail not only to complement the plaque-forming defect of an ICP0-null mutant virus but a

24 ICP0-null mutant HSV-1 exhibits a plaque-forming defect of up to 3 orders of magnitude in

25 prototype of a family of large, icosahedral, plaque-forming, double-stranded-DNA-containing viruses t

26 prototype of a family of large, icosahedral, plaque-forming, dsDNA viruses that replicate in certain

27 lular replication measured by a reduction in plaque-forming efficiency and plaque size.

28 that depletion of CoREST should improve the plaque-forming efficiency and replication of ICP0 null m

29 018 and performed 3D structural analysis and plaque-forming efficiency assay.

30 man cytomegalovirus (HCMV) infection, as its plaque-forming efficiency increased in MORC3-depleted ce

31 Plaque-forming efficiency was enhanced at least 50-fold

32 ation of GPI-anchored prions, with fibrillar plaques forming from poorly glycosylated, GPI-anchorless

33 effect only in human cell lines, with large plaques forming in HeLa cells, with minimal cell associa

34 Tg2576 beta-amyloid-plaque-forming mice should be a useful system for assess

35 Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-ass

36 of this unique FKBP-dependence, spontaneous plaque-forming mutants of phi X174 were isolated on a sl

37 ed in large numbers (>5 x 10(8)/ml), and the plaque-forming particle (PFP) titer dropped approximatel

38 he ratios of cell-killing particles (CKP) to plaque-forming particles (PFP) were 1:1 and 7:1 in popul

39 ically active particles of infectious virus (plaque-forming particles [PFPs]) and different classes o

40 ne with active alleles of Bax/Bak results in plaque-forming phages.

41 The growth of the ICP10DeltaPK virus and its plaque-forming potential were restored to wild-type leve

42 lycosylated PrP (Prnp187N) challenged with a plaque-forming prion strain showed a phenotype reversal,

43 96Q mice challenged with 2 subfibrillar, non-plaque-forming prion strains instead developed plaques h

44 tein, and the virus had wild-type growth and plaque-forming properties.

45 Furthermore, two naturally occurring plaque-forming revertants were analyzed and shown to hav

46 in a location unique to APP genes of amyloid plaque-forming species and absent in all other genes sur

47 6) present only in the APP gene from amyloid plaque-forming species, absent in all APP-like-proteins'

48 uding amyloid plaque-forming and non-amyloid plaque-forming species, and of prions (27 different DNA

49 es that often equal and sometimes exceed the plaque-forming titer of the inducing phage.

50 tion of the dengue 2 and dengue 3 viruses in plaque forming unit (PFU mL(-)(1)), giving detection lim

51 ectrodes enable the detection of less than 1 plaque forming unit (pfu)/mL in a direct EIS assay.

52 arget FAdVs and the electric signal up to 10 Plaque forming unit (PFU)/mL with a limit of detection (

53 Human cytomegalovirus (5 x 10(3) plaque forming unit in 0.1 ml Hank's balanced salt solut

54 acyclovir-resistant strain) was measured by plaque-forming unit (PFU) inhibition.

55 LS) regression correlating NIRS spectra with plaque-forming unit (PFU) measurements.

56 phal retention of phages of up to ~4 x 10(7) plaque-forming unit (PFU) mm(-2) (~2550 PFU mm(-2) s(-1)

57 5% chlorine was sufficient to ensure <8 Phi6 plaque-forming unit (PFU)/cm(2) in all tests.

58 roporation into cells, producing 2.9 x 10(6) plaque-forming unit (PFU)/mL of virus.

59 d titer equivalents 8.01 x 106 to 2.45 x 100 plaque-forming unit (PFU)/mL.

60 tion values, we injected intradermally 10(9) plaque-forming unit adenovirus with the following transg

61 ted [ITT-I] population) or RSV RNA >=1 log10 plaque-forming unit equivalents (PFUe)/mL (specific inte

62 nd received primary vaccination with 2x10(7) plaque-forming unit per mL of VSVDeltaG-ZEBOV-GP.

63 ous inoculation with 0.5 ml of a 1.4 x 10(3) plaque-forming unit per ml suspension of the attenuated

64 I.v. injections of GLV-1h68 (1x10(7) plaque-forming unit per mouse) into nude mice with estab

65 gle intratumoral administration of 2 x 10(9) plaque-forming unit(s) of Ad-OC-E1a.

66 l-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated from the fitt

67 tions were found to contain more genomes per plaque-forming unit, with larger diameters.

68 oratory RUB strains and as low a dose as one plaque-forming unit.

69 requencies ranging from 10(-5) to 10(-9) per plaque-forming unit.

70 (HCMV) at a multiplicity of infection of 0.1 plaque-forming unit/cell and remained > 95% viable even

71 l load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equivalents [PFUe] x hours per milli

72 roup were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equivalents x hours per milliliter,

73 NP) and matrix protein 1 (M1) at 1.5 x 10(8) plaque forming units (4.3 x 10(8) 50% tissue culture inf

74 Challenge with 10,000 plaque forming units (PFU) of EBOV was uniformly lethal,

75 es the viral titers remain high (10(5)-10(8) plaque forming units (pfu) per gram of tissue) for the l

76 ure injections of > 20 nanoliters of a 10(8) plaque forming units (pfu) per ml solution of virus were

77 Ad5CMVcatalase, with up to 10 plaque forming units (pfu) per neuron, did not affect ce

78 for vaccination containing either 1 x 10(7) plaque forming units (PFU) VSV-SUDV or 1 x 10(7) PFU of

79 1 through 5 in four dose cohorts: 1 x 10(9) plaque forming units (pfu), 1 x 10(10) pfu, 3 x 10(10) p

80 st generation assay is 10(2) and 10(2)-10(8) plaque forming units (pfu), respectively.

81 at a multiplicity of infection (MOI) of 10.0 plaque forming units (pfu)/cell at 48 hours.

82 infect SK-ChA-1 and HeLa cells at 10 and 100 plaque forming units (pfu)/cell, followed by FACS analys

83 re inoculated intramuscularly with 6 x 10(3) plaque forming units (PFUs) of MP-12 vaccine.

84 xpressing Cre recombinase (Ad-Cre; 2 x 10(7) plaque forming units [PFU]) and adeno-associated viral v

85 Murine cytomegalovirus (9 x 10(2) plaque forming units [pfu]) was injected into the suprac

86 7 A(H5N1) virus-using a liquid inoculum (106 plaque forming units [PFU]), aerosol inhalation (15-16 P

87 Each mouse received 1 x 10(9) plaque forming units administered i.v. 48 hr before the

88 ion of MV-CEA at a total dose of 1.8 x 10(6) plaque forming units as assessed by magnetic resonance i

89 tein, 120 fg for nucleocapsid protein, and 7 plaque forming units for intact virus, all within <30 mi

90 Our data show 5-log reduction in plaque forming units from a single lamp (single- pass an

91 were treated with a total dose of 8 x 10(7) plaque forming units of MV-CEA, administered i.v.

92 4 followed by intramuscular injection of 108 plaque forming units of MVA-CMDR at weeks 12 and 24.

93 sed by the reduction in viral genomes and/or plaque forming units on treatment.

94 pounds exhibiting clinically relevant (10(1) plaque forming units) limit of detection.

95 intratracheally with a high dose (3 x 10(6) plaque forming units) of SARS-CoV-2.

96 y probed by evaluating infective virions (as plaque forming units) or genomic damage (via the quantit

97 ins of HSV-1-sensitive A/J mice at 2 x 10(6) plaque forming units, G47Delta was as safe as G207.

98 mits of detection equivalent to less than 50 plaque forming units/mL (PFU/mL) were determined with vi

99 tilation at one of two concentrations (~1010 plaque forming units/mL or ~1011 plaque forming units/mL

100 sensitive in vitro yet grew robustly (>10(7) plaque forming units/mL) at the permissive temperature.

101 of an adenoviral construct (10 muL; 8x10(9) plaque forming units/mL) encoding green fluorescent prot

102 ions (~1010 plaque forming units/mL or ~1011 plaque forming units/mL).

103 units; 70% for animals that received 3 x 10 plaque forming units; 0% for controls; p < 0.01 for each

104 ntrols (60% for animals that received 3 x 10 plaque forming units; 70% for animals that received 3 x

105 Plaque-forming units (106 or 108) of an adenovirus conta

106 rs, one eye was injected once with 8 X 10(8) plaque-forming units (20 microl) of the viral vector, wh

107 laque-forming units (low dose) and 4 x 10(8) plaque-forming units (high dose) of rPLTP.AdV into mice,

108 After intravenous infusion of 4 x 10(7) plaque-forming units (low dose) and 4 x 10(8) plaque-for

109 lthy adults were inoculated with 5.0 log(10) plaque-forming units (PFU) (n = 30) or 3.0 log10 PFU (n

110 oV-2 aerosol emission rates are high (>1,000 Plaque-forming units (PFU) / min).

111 d aerosol and average air detection was 1.00 plaque-forming units (pfu) and 0.08 pfu/m(3), respective

112 ine at 3 million, 20 million and 100 million plaque-forming units (PFU) and homologous VSV-Ebola vacc

113 t time points after inoculation of 2 x 10(4) plaque-forming units (PFU) HSV-1 (KOS strain) or an equi

114 ial (vaccine to placebo ratio, 2:1) at 105.7 plaque-forming units (PFU) in 15 RSV-seropositive 12- to

115 ed trial (vaccine-placebo ratio, 2:1) at 106 plaque-forming units (PFU) in 15 RSV-seropositive childr

116 roduces 45% survivors at a dose of 3 x 10(4) plaque-forming units (pfu) in a 9-day-old mouse model of

117 ted Ebola virus disease when used at 2 x 107 plaque-forming units (PFU) in a trial in Guinea.

118 ived 1 subcutaneous dose of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3.

119 g ZIKV in oral samples with sensitivity of 5 plaque-forming units (PFU) in less than 40 min.

120 IL-17 cDNA targeted to the liver (5 x 10(9) plaque-forming units (PFU) intravenous) resulted in a tr

121 human bilirubin-UGT1 (Ad-hBUGT1) (3 x 10(9) plaque-forming units (pfu) intravenously) in adult bilir

122 3) were injected with 1 x 10(6) to 5 x 10(8) plaque-forming units (pfu) of Ad-hSSTr2-TK.

123 by subcutaneous inoculation of either 10(3) plaque-forming units (PFU) of DENV-1 or 10(5) PFU of DEN

124 9 days after intranasal infection with 10(5) plaque-forming units (pfu) of Influenza A strain WSN/33.

125 dult mice following infection with 5 x 10(5) plaque-forming units (PFU) of LACV.

126 -24 months received 1 intranasal dose of 105 plaque-forming units (PFU) of LID/DeltaM2-2/1030s (n = 2

127 Rhesus macaques given 5 x 10(4) or 1 x 10(5) plaque-forming units (pfu) of Rift Valley fever (RVF) MP

128 M-N95 respirator were inoculated with 10(6) plaque-forming units (PFU) of SARS-CoV-2 and were UV irr

129 infected with 10(4), 10(5), 10(6), or 10(7) plaque-forming units (pfu) of the Dryvax strain of the v

130 l BALB/c mice were inoculated with 4 X 10(4) plaque-forming units (PFU) of the KOS strain of HSV-1 us

131 t doses (3 x 10(8), 1 x 10(8), and 3 x 10(7) plaque-forming units (pfu) of the recombinant adenoviral

132 ty results in volunteers receiving 3 x 10(5) plaque-forming units (pfu) of the recombinant vesicular

133 ccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per millili

134 This strategy yielded >1 x 10(3) plaque-forming units (pfu) of virus per ml of supernatan

135 fter nude mice were injected i.p. with 10(7) plaque-forming units (pfu) of WT, TK-, VGF-, or vvDD-GFP

136 f vaccine ranging from 300,000 to 50 million plaque-forming units (PFU) or placebo.

137 3 strain Dearing (T3D) at 0, 0.1, 1, and 10 plaque-forming units (PFU) per cell for 48 h.

138 OOP where CBA/J mice infected with 1 x 10(6) plaque-forming units (PFU) reovirus 1/L develop follicul

139 ymic BALB/c mice was injected with 1 x 10(4) plaque-forming units (PFU) to 2 x 10(4) PFU of herpes si

140 eived ONYX-015 at a daily dose of 1 x 10(10) plaque-forming units (pfu) via intratumoral injection fo

141 ts received a single vaccine dose of 2x10(4) plaque-forming units (PFU), 2x10(5) PFU, 2x10(6) PFU, or

142 atment groups: ChimeriVax-WN02 3.7- x -10(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3)

143 ore permissive SCID mice with 10(5) or 10(7) plaque-forming units (PFU), respectively.

144 ect VV in concentrations from 10(3) to 10(8) plaque-forming units (PFU), with a limit of detection of

145 o be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu).

146 were injected with doses of up to 1 x 10(11) plaque-forming units (pfu).

147 ngeal virus titers peaked at 10(5.0)-10(6.0) plaque-forming units (pfu)/g of tissue from days 2 throu

148 A first-dose MTD of 12 x 10(9) plaque-forming units (PFU)/m(2) was established for outp

149 mits of detection for EBOV and SUDV were 465 plaque-forming units (PFU)/mL (1010 copies/mL) and 324 P

150 rmissive cell lines produced less than 0.7-7 plaque-forming units (PFU)/mL and in susceptible mice le

151 tation (LoQ) of the sensor are 1.28 and 3.89 plaque-forming units (PFU)/mL for S protein and 1.45 and

152 eceiving infectious titers of > or = 4X10(9) plaque-forming units (pfu)/mL showed endothelial activat

153 ection of this RT-LAMP assay was 2.8 x 10(2) plaque-forming units (PFU)/test and 1 x 10(3) PFU/test w

154 in 96-well plates was approximately 2 x 106 plaque-forming units (pfu)/well.

155 s, as revealed by their LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA

156 In the open-label cohort, 1.0 x 10(7) plaque-forming units (PFU; low dose), 1.0 x 10(8) PFU (m

157 of detection (LOD) for each test using viral plaque-forming units (PFUs) and viral RNA copy numbers o

158 solvents to yield on average 23 mL of 10(11) plaque-forming units (PFUs) per milliliter for Pseudomon

159 days before challenge with either 1 x 10(7) plaque-forming units (PFUs) VSV-SUDV, VSV-EBOV, or contr

160 d hospitalized patients (log(10) 3.7 +/- 1.7 plaque-forming units (PFUs)/mL vs 2.4 +/- 1.1 PFUs/mL, P

161 various vector doses [1 x 10(6) to 2 x 10(9) plaque-forming units (PFUs)] prior to imaging.

162 tion (one 0.5 mL dose containing 2.5 x 10(4) plaque-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of

163 After ocular challenge with 2 x 10(5) plaque-forming units [pfu] per eye of HSV-1 strain McKra

164 needle with undiluted vaccine (dose, 10(7.8) plaque-forming units [pfu] per milliliter), a 1:10 dilut

165 n of HSV-1 strain McKrae (25 microL of 10(5) plaque-forming units [PFU]) in the scarified rabbit corn

166 Administration of a high dose (4 x 10(9) plaque-forming units [pfu]) of Av1ALAPH81 to mice result

167 istency lots of rVSVDeltaG-ZEBOV-GP (2 x 107 plaque-forming units [pfu]), high-dose 1 x 108 pfu, or p

168 received RSV/DeltaNS2/Delta1313/I1314L (106 plaque-forming units [PFU]), RSV/276 (105 PFU), or place

169 ose levels of Adp53 (1 x 10(6) to 1 x 10(11) plaque-forming units [PFU]).

170 ein (rVSV G-ZEBOV-GP; 3 x 10(5) to 1 x 10(8) plaque-forming units [pfu]).

171 (rVSVDeltaG-ZEBOV-GP; 3 x 10(5) to 1 x 10(8) plaque-forming units [pfu]).

172 in these models at low doses of EBOV (</=100 plaque-forming units [PFU]).

173 e doses of the rVSV-ZEBOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 milli

174 1 of 3 lots of rVSVDeltaG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combined-lots group

175 inally in adult pigmented rabbits (5 x 10(4) plaque-forming units [pfu]/eye).

176 ntrations associated with HFNO (2.66 x 10(4) plaque-forming units [PFU]/L of air sampled), nasal pron

177 ildren (mean peak titer, 10(4.3) vs. 10(2.5) plaque-forming units [pfu]/mL), indicating that the 1030

178 6-24 months received 1 intranasal dose (105 plaque-forming units [PFUs] of D46/NS2/N/DeltaM2-2-HindI

179 le intramuscular dose of rVSV-ZEBOV (2x10(7) plaque-forming units administered in the deltoid muscle)

180 ncubation, and in less than 20 h it detected plaque-forming units at rates higher than 90% at 100% sp

181 , gene transfer was performed with 1 x 10(9) plaque-forming units by intravenous tail injection, 48 h

182 knockout (ko) mice were infected with 10(5) plaque-forming units CVB3.

183 An HBRV dose of > or =8 x 10(6) plaque-forming units has demonstrated 68.8%-76.6% effica

184 owing to an increased ratio of particles to plaque-forming units in infections with the former.

185 + mice and was associated with increased RSV plaque-forming units in lung homogenates.

186 48/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broad

187 In vivo, Ad-hACE2-eGFP infection (2x10(6) plaque-forming units intracerebroventricularly) produced

188 MBaMV replication reached 10(3)-10(5) plaque-forming units ml(-1) in human epithelial cell lin

189 (a surrogate virus for SARS-CoV-2) at ~10(8) plaque-forming units mL(-1), reflecting the upper limits

190 Mice were then given 10(9) plaque-forming units of a control vector (Ad.LacZ) or Ad

191 A single i.v. administration of 2 x 10(9) plaque-forming units of Ad-hOC-E1 inhibited the growth o

192 Using 1x10(9) plaque-forming units of Ad-LacZ (multiplicity of infecti

193 Intralesional injection of 5 x 10(8) plaque-forming units of AdCIFN-beta (but not AdLacZ) era

194 a single intravenous injection of 3 x 10(9) plaque-forming units of AdmVLDLR.

195 tu with saline alone (control), or 9 x 10(9) plaque-forming units of AdV-FasL.

196 First, 1.0 x 10(9) plaque-forming units of AdvBcl-2 in phosphate-buffered s

197 delay in healing, with vehicle, 106, or 108 plaque-forming units of an adenovirus containing the pla

198 Ischemic excisional wounds treated with 108 plaque-forming units of an adenovirus containing the pla

199 mean +/- SD, p < 0.05) when treated with 106 plaque-forming units of an adenovirus containing the pla

200 ean +/- SD, p < 0.001) when treated with 108 plaque-forming units of an adenovirus containing the pla

201 nstillation of either 1 x 10(9) or 4 x 10(9) plaque-forming units of an adenovirus that expresses an

202 A dose of 2 x 10(9) plaque-forming units of apoE4-expressing adenovirus redu

203 HepG2 cells were infected with 2 x 10(5) plaque-forming units of AvRB15 for 5, 10, 15, and 24 h.

204 oculated seven cynomolgus macaques with 1000 plaque-forming units of BDBV, administering rVSVDeltaG/B

205 bjects were inoculated intranasally with 100 plaque-forming units of coxsackievirus A21.

206 ) were infected intraperitoneally with 10(6) plaque-forming units of CVB3.

207 surfactant-based system to deliver 4 x 10(9) plaque-forming units of E1a-/E3- recombinant adenovirus

208 45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compare

209 esus macaques received a target dose of 1000 plaque-forming units of Ebola virus intramuscularly with

210 Dams were challenged with 1 x 10(4) plaque-forming units of GPCMV in the third trimester.

211 ere intracamerally infected with 2.5 x 10(4) plaque-forming units of infectious HSV-1.

212 DIVER can detect 1 x 10(5) liposomes and 100 plaque-forming units of lentivirus and can successfully

213 fter supraciliary injection with 9.0 x 10(2) plaque-forming units of MCMV, 7 of 10 NK-depleted mice d

214 amide, were infected subretinally with 5x102 plaque-forming units of MCMV.

215 DBA/1 LacJ mice were administered 3 x 10(8) plaque-forming units of mIL-12 i.p. in a nonreplicating

216 ow-femtomole range, as estimated by titering plaque-forming units of MS2.

217 (1:1) to receive a single dose of 2 x 10(8) plaque-forming units of MVA-BN-Filo or saline placebo.

218 after intradermal vaccination with 5 x 10(7) plaque-forming units of MVA85A.

219 ) scid mice, which received 0.5 or 5 x 10(6) plaque-forming units of R4009, either were coinoculated

220 Patients with mCRPC received 2x10(8) plaque-forming units of recombinant vaccinia PSA-Tricom

221 ults were inoculated intranasally with 10(6) plaque-forming units of rHMPV-SHs.

222 BALB/c mice were infected with 10(7) plaque-forming units of RSV, in the presence or absence

223 provider to subcutaneous injections of 10(8) plaque-forming units of TG4010 or placebo from the begin

224 Rabbit eyes were infected with 10(5) plaque-forming units of the Dryvax strain of vaccinia vi

225 ere inoculated subcutaneously with 3.0 log10 plaque-forming units of the Guanarito virus prototype st

226 rsity of Wisconsin solution containing 10(9) plaque-forming units of the recombinant adenovirus.

227 ulation of CMV ocular infection, 9.0 x 10(2) plaque-forming units of the Smith strain of murine CMV (

228 her 2.5 x 10(5), 2.5 x 10(6), or 2.5 x 10(7) plaque-forming units of vaccine.

229 All mice vaccinated with 1 x 10(7) plaque-forming units of wild-type E7-vaccinia showed pro

230 enged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV.

231 V)CFTR.10 at doses of 3 x 10(6) to 2 x 10(9) plaque-forming units over 9 months by endobronchial spra

232 ion with RAd35 beta-Gal at 30, 100, and 1000 plaque-forming units per cell (pfu/cell), expression of

233 SERCA virus titers >5 to 6 plaque-forming units per cell produced overcrowding of A

234 At higher input multiplicities (10 plaque-forming units per cell), ADsubUL82 grew nearly as

235 ricted at low input multiplicities (0.01-0.1 plaque-forming units per cell), producing a yield that i

236 At mois > 3 plaque-forming units per cell, virus replication and pro

237 CA virus titer were maintained within 1 to 4 plaque-forming units per cell.

238 tectable by flow cytometry at an MOI of > 30 plaque-forming units per cell.

239 omegalovirus promoter at approximately 10(8) plaque-forming units per cornea for 48 hours.

240 after corneal scarification with 1.5 x 10(6) plaque-forming units per eye with one of the following r

241 e treated with CMX001 had titers 3-5 log(10) plaque-forming units per gram of tissue lower than sampl

242 ee animals received 1 x 10(10) to 1 x 10(11) plaque-forming units per kilogram by intravenous injecti

243 target, at low concentration values of 3-45 plaque-forming units per milliliter (pfu mL(-1)) with de

244 toilets at an initial concentration of 10(7) plaque-forming units per milliliter (PFU mL(-1)), were n

245 ney cells and achieved levels of 10(6)-10(7) plaque-forming units per ml of cell supernatant 6 days a

246 dicated by: high titres of MARV (10(3)-10(5) plaque-forming units per mL); development of leucocytosi

247 Rats transduced with 1x10(9) plaque-forming units show decremental cardiac luciferase

248 hosphamide-suppressed animals, the ratios of plaque-forming units to LD50 decreased by at least four

249 nfection, but it did not alter the ratios of plaque-forming units to LD50 or affect the HSV-induced i

250 s evidenced by decreased viral titers (10(5) plaque-forming units to undetectable), and restoration o

251 1) (P<0.05 for 1x10(9), 1x10(8), and 1x10(7) plaque-forming units versus control adenovirus-expressin

252 say, 50 microm BIP caused a 50% reduction in plaque-forming units with either virus.

253 es of either CCSV or test vaccine (2.5x10(5) plaque-forming units) by 15 puncture scarification in do

254 wing day, they received G207 (10(7) or 10(8) plaque-forming units) by controlled-rate infusion over a

255 injection of recombinant adenoviruses (10(9) plaque-forming units) encoding the ligand-binding ectodo

256 The effect of rat CMV (RCMV) (5x105 plaque-forming units) on TVS (neointimal index, NI) and

257 enous (IV) injection of GLV-1h153 (1 x 10(7) plaque-forming units) or phosphate buffered saline was t

258 given two doses of 89-12 (containing 1x10(5) plaque-forming units) or placebo, and 213 were followed

259 a single injection of AdRSVpHyde (5 x 10(9) plaque-forming units) reduced DU145 tumors in nude mice

260 njection of tumors with Ad.mIL-12 (1 x 10(9) plaque-forming units) results in a complete tumor regres

261 ro with adenovirus murine FVIII (3.3 x 10(5) plaque-forming units) was 87%.

262 lication-incompetent adenovirus (0-2 x 10(9) plaque-forming units) with the E1 region deleted (n = 8)

263 In rats dosed with this agent (2.2 x 10(9) plaque-forming units), the time course of expression was

264 ) were injected with AdSDF-1alpha (5 x 10(8) plaque-forming units), there was an accumulation of dend

265 fection with the unadapted virus (ID(50) = 5 plaque-forming units).

266 ty when inoculated i.v. in high doses (10(9) plaque-forming units).

267 The labeled phage (10(9) plaque-forming units, 1-3.7 MBq) was administered either

268 ation with rVSV-ZEBOV (one dose of 2 x 10(7) plaque-forming units, administered intramuscularly in th

269 ice were infected with adenovirus (3 x 10(9) plaque-forming units, intravenously) containing either C

270 , did not appreciably affect HSV-1 function (plaque-forming units, normalized to viral particles meas

271 1, with subsequent monthly boosts of 1x10(9) plaque-forming units, starting on day 15.

272 antifies the infected area and the number of plaque-forming units.

273 in cell cultures ranged from 10(1) to 10(3) plaque-forming units/0.5 mL of a 10% stool suspension.

274 i.v. administration of CG8840 (3.33 x 10(9) plaque-forming units/animal on day 1) and docetaxel (20

275 of 100% at a multiplicity of infection of 25 plaque-forming units/cell and persistence of foreign gen

276 ion of breast cancer cells with AdWTp53 (100 plaque-forming units/cell) resulted in 100% loss of the

277 ts received 3 oral doses of vaccine (4 x 105 plaque-forming units/dose) or placebo at ages approximat

278 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

279 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

280 Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitiv

281 ng units/mL; after 3 weeks, </= 4 mL x 10(8) plaque-forming units/mL every 2 weeks).

282 12), a cocktail of four phages (2-3 x 10(9) plaque-forming units/ml of 2003, 2002, 3A, and K; n = 12

283 ere labeled by directly injecting 8 x 10(10) plaque-forming units/ml of adenoviral GFP in 20-100 micr

284 V assay sensitivity was determined to be 3.2 plaque-forming units/mL using a reference virus culture

285 administered intratumorally in week 1 (10(6) plaque-forming units/mL), then in week 4 and every 2 wee

286 l vector used at identical titer (1 x 10(10) plaque-forming units/ml).

287 n week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

288 MV-ERV grew to 10(6) plaque-forming units/mL, slightly lower than the parenta

289 ms and shed live virus as high as 4.13 x 103 plaque-forming units/mL.

290 egan in week 1 (first dose, </= 4 mL x 10(6) plaque-forming units/mL; after 3 weeks, </= 4 mL x 10(8)

291 ns of Ad-FHIT, at a total dose of 3 x 10(10) plaque-forming units/tumor for H1299 tumors and 4 x 10(1

292 eas were inoculated bilaterally with 2x10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) af

293 A strain, small (DA-D(S)) or large (DA-C(L)) plaque forming variants, revealed differences in the dis

294 5804Han89 (CDV(5804)), the small- and large-plaque-forming variants of the CDV vaccine strain Onders

295 odnaviridae, is a large double-stranded DNA, plaque-forming virus that infects the unicellular green

296 n yet completely eliminated the formation of plaque-forming virus.

297 hloroviruses are large, double-stranded-DNA, plaque-forming viruses that infect certain eukaryotic ch

298 e of a family of large, double-stranded DNA, plaque-forming viruses that infect certain eukaryotic ch